Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Membrane proteomics in P493-6 cells treated with NMTi

ABSTRACT: N-myristoyltransferase inhibitors (NMTi) are promising novel anti-cancer agents, including in MYCN-amplified neuroblastoma and Burkitt’s lymphoma, but a mechanistic rationale for targeted therapy is still poorly defined. A key function of N-myristoylation is to mediate membrane localisation. We therefore carried out membrane proteomics on the P493-6 cell line +/- NMTi. Identification of PPIs between affected proteins via STRING allowed the identification of heavily affected biological nodes, including respiratory complex I. This study provides a mechanistic rationale for NMTi in MYC-deregulated cancers.

INSTRUMENT(S): timsTOF HT

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell

SUBMITTER: James Zhang

LAB HEAD: Edward W. Tate

PROVIDER: PXD054019 | Pride | 2025-07-27

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	P4936_Experimental_samples.csv	Csv
	SV_P4936_MYC_HIGH_DET_R1_S1-E12_1_930.d.quant	Other
	SV_P4936_MYC_HIGH_DET_R1_S1-E12_1_930.d.zip	Other
	SV_P4936_MYC_HIGH_DET_R2_S1-F1_1_931.d.quant	Other
	SV_P4936_MYC_HIGH_DET_R2_S1-F1_1_931.d.zip	Other

Items per page:

1 - 5 of 19

Similar Datasets

Membrane proteomics in SHEP21N cells treated with NMTi

Project description:N-myristoyltransferase inhibitors (NMTi) are promising novel anti-cancer agents, including in MYCN-amplified neuroblastoma and Burkitt’s lymphoma, but a mechanistic rationale for targeted therapy is still poorly defined. A key function of N-myristoylation is to mediate membrane localisation. We therefore carried out membrane proteomics on the SHEP21N cell line +/- NMTi. Identification of PPIs between affected proteins via STRING allowed the identification of heavily affected biological nodes, including respiratory complex I. This study provides a mechanistic rationale for NMTi in MYCN-amplified neuroblastoma.

2025-07-27 | PXD054008 | Pride

MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition - DoHH2 proteomics

Project description:Human N-myristoyltransferases (NMTs) catalyze N-terminal protein N-myristoylation and are promising targets in cancer, with an emerging mechanistic rationale for targeted therapy. Here, we screened 245 cancer cell lines against IMP-1320, a potent NMT inhibitor (NMTi), and conducted pathway-level analyses to identify that deregulated MYC increases cancer cell sensitivity to NMTi. Proteomics on detergent-enriched membrane fractions in MYC or MYCN-deregulated cancer cell models revealed that cell death is associated at least in part with loss of membrane association of mitochondrial respiratory complex I. This is concurrent with loss of myristoylation and degradation of the complex I assembly factor NDUFAF4, and induction of mitochondrial dysfunction, driven by MYC or MYCN-deregulation. NMTi eliminated or suppressed MYC and MYCN-driven tumors in vivo without overt toxicity, suggesting that this constitutive co-translational protein modification can be targeted in MYC-driven cancers. This dataset comprises the proteomic data obtained from DoHH2 tumours, excised from CB17/SCID mice treated intraperitoneally with vehicle or IMP1320 (25 mg/kg/day), on a three days on/three days off dosing schedule.

2025-07-30 | PXD063851 | Pride

MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition - Th-MycN tumour proteomics

Project description:Human N-myristoyltransferases (NMTs) catalyze N-terminal protein N-myristoylation and are promising targets in cancer, with an emerging mechanistic rationale for targeted therapy. Here, we screened 245 cancer cell lines against IMP-1320, a potent NMT inhibitor (NMTi), and conducted pathway-level analyses to identify that deregulated MYC increases cancer cell sensitivity to NMTi. Proteomics on detergent-enriched membrane fractions in MYC or MYCN-deregulated cancer cell models revealed that cell death is associated at least in part with loss of membrane association of mitochondrial respiratory complex I. This is concurrent with loss of myristoylation and degradation of the complex I assembly factor NDUFAF4, and induction of mitochondrial dysfunction, driven by MYC or MYCN-deregulation. NMTi eliminated or suppressed MYC and MYCN-driven tumors in vivo without overt toxicity, suggesting that this constitutive co-translational protein modification can be targeted in MYC-driven cancers. This dataset comprises the proteomic data obtained from Th-MycN tumours, excised from 129SvJ mice treated intraperitoneally with vehicle or IMP1320 (25 mg/kg/day), on a three days on/four days off dosing schedule.

2025-07-30 | PXD063661 | Pride

MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition - Mitochondrial fractionation

Project description:Human N-myristoyltransferases (NMTs) catalyze N-terminal protein N myristoylation and are promising targets in cancer, with an emerging mechanistic rationale for targeted therapy. Here, we screened 245 cancer cell lines against IMP-1320, a potent NMT inhibitor (NMTi), and conduced pathway-level analyses to identify that deregulated MYC increases cancer cell sensitivity to NMTi. Proteomics on detergent enriched membrane fractions in MYC or MYCN deregulated cancer cell models revealed that cell death is associated at least in part with loss of membrane association of mitochondrial respiratory complex I. This is concurrent with loss of myristoylation and degradation of the complex I assembly factor NDUFAF4, and induction of mitochondrial dysfunction, driven by MYC or MYCN deregulation. NMTi eliminated or suppressed MYC and MYCN-driven tumors in vivo without overt toxicity, suggesting that this constitutive co translational protein modification can be targeted in MYC driven cancers.

2025-07-30 | PXD056941 | Pride

C-terminal amides mark proteins for degradation via SCF/FBXO31

Project description:FBXO31 is a substrate adapter for the SCF-type ubiquitin ligase complex SCF/FBXO31 which ubiquitylates C-terminal amide-bearing proteins (CTAPs), thereby triggering their proteasomal degradation in human cells. Profiling of active cullin-RING ubiquitin E3 ligases was performed in naive or FBXO31 knockdown cell lines treated with hydrogen peroxide.

2024-11-07 | PXD055518 | Pride

Crosstalk between the glucocorticoid and mineralocorticoid receptor boosts glucocorticoid-induced killing of multiple myeloma cells

Project description:The glucocorticoid receptor (GR) is a crucial drug target in multiple myeloma as its activation with glucocorticoids effectively triggers myeloma cell death. However, as high-dose glucocorticoids are also associated with deleterious side effects, novel approaches are urgently needed to improve GR’s action in myeloma. Here we reveal a functional crosstalk between GR and the mineralocorticoid receptor (MR) that culminates in improved myeloma cell killing. We show that the GR agonist Dexamethasone (Dex) downregulates MR levels in a GR-dependent way in myeloma cells. Co-treatment of Dex with the MR antagonist Spironolactone (Spi) enhances Dex-induced cell killing in primary, newly diagnosed GC-sensitive myeloma cells, while in a relapsed GC-resistant setting, Spi alone induces distinct myeloma cell killing. On a mechanistic level, we find that a GR-MR crosstalk is arising from an endogenous interaction between GR and MR in myeloma cells. Quantitative dimerization assays show that Spi reduces Dex-induced GR-MR heterodimerization and completely abolishes Dex-induced MR MR homodimerization but leaves GR-GR homodimerization intact. Unbiased transcriptomics further reveals that c-myc and many of its target genes are downregulated most by Dex and Spi combined, while proteomics analyses identify that several metabolic hallmarks are modulated most by this combination treatment. Finally, we identified a subset of Dex+Spi downregulated genes and proteins that may predict prognosis in the CoMMpass patient cohort. Our study demonstrates that GR-MR crosstalk is therapeutically relevant in myeloma as it provides novel strategies towards glucocorticoid-based dose-reduction.

2023-10-24 | PXD043635 | Pride

Specific cPRC1 complexes are co-opted to mediate oncogenic gene repression in diffuse midline glioma

Project description:Diffuse midline glioma (DMG) is a fatal childhood brain tumour characterised primarily by mutant histone H3 (H3K27M). H3K27M causes a global reduction in Polycomb Repressive Complex 2 (PRC2)-mediated H3K27me3 by inhibiting PRC2 enzymatic activity. Paradoxically, PRC2 is essential in DMG tumour cells where residual complex activity is required for oncogenic gene repression, although the molecular mechanisms acting downstream of PRC2 in this context are poorly understood. Here, we’ve discovered this oncogenic gene repression is mediated by specific canonical PRC1 (cPRC1) formations. By combining CRISPR screening, biochemical and chromatin mapping approaches with functional perturbations we show that cPRC1 complexes containing CBX4 and PCGF4 drive oncogenic gene repression downstream of H3K27me3 in DMG cells. Remarkably, the altered H3K27me3 modification landscape characteristic of these tumours rewires the distribution of cPRC1 complexes on chromatin. CBX4 and PCGF4 containing cPRC1 accumulate at sites of H3K27me3 while other cPRC1 formations are displaced. Despite accounting for <5% of cPRC1 complexes in DMG, CBX4/PCGF4-containing complexes predominate as gene repressors. Our findings link the altered distribution of H3K27me3 with imbalanced cPRC1 function, promoting oncogenic gene repression in DMG cells, revealing new disease mechanisms and highlighting potential therapeutic opportunities in this incurable childhood brain tumour.

2025-06-24 | PXD058532 | Pride

Project description:A mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia

| PRJNA232633 | ENA

Effect of NMT inhibition on a model of NALFD in mice

Project description:To examine the effects of NMTi treatment on progression of NAFLD model, mice on chow or high-fat diet were treated with vehicle or additionally on high-fat diet treated with DDD86481. Transcriptional analysis was performed after 19 weeks of high-fat diet with monthly treatments with 3 rounds of NMT inhibitor treatment.

2023-09-28 | GSE224069 | GEO

Mus musculus

Project description:A mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia [array]

| PRJNA232634 | ENA